Monkeypox Vaccine, Drug Pipeline Grows Despite Signs Of Slowing Infections

Since it began spreading in the spring and migrated to the US shortly thereafter, monkeypox has yet to explode from an outbreak into a bigger epidemic, let alone a pandemic, and infection rates are already showing signs of plateauing in many areas. Still, the world isn’t out of the woods yet, with large-scale growth of infections still possible. To that end, a small pipeline of drug and vaccine candidates has emerged, many of them repurposed products originally developed for smallpox, despite some hitches in getting programs off the ground.

The US Centers for Disease Control has reported 21,504 cases of monkeypox in the US, while the World Health Organization reported 52,996 cases across 102 countries between 1 January and 7 September. WHO director-general Tedros Adhanom Ghebreyesus said in 25 August remarks that the epicenter of the outbreak had moved from Europe to the Americas